BIO hails Obama R&D national vision

28 April 2009

The US Biotechnology Industry Organization has hailed President Barack Obama's call for a national target of 3% of the nation's Gross Domestic  Product to be spent on scientific R&D. Jim Greenwood, the BIO's  president and chief executive, said: "America's biotechnology community  thanks Pres Obama for setting this ambitious goal. As the President  said: 'science is more essential for our prosperity, our security, our  health, our environment and our quality of life than it has ever been.'  We couldn't agree more."

Mr Greenwood emphasized the 1.3 million people employed in the US  bioscience sector, arguing that "our industry can help drive economic  growth in innovation industries," including  pharmaceuticals.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight